/
RZLT
$5.10+$0.06 (+1.19%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$485.3M
96M shares
52-week range
$1.07 – $11.46
39% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-9.17
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.1M | $48.0K | $18.0K | $13.0K | $0 | $0 | $0 | $0 |
| Gross profit | −$1.1M | −$48.0K | −$18.0K | −$13.0K | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $17.3M | $19.1M | $14.4M | $15.0M | $32.5M | $43.8M | $55.7M | $61.5M |
| Operating income | −$28.7M | −$25.9M | −$20.5M | −$22.9M | −$41.8M | −$56.0M | −$70.4M | −$79.9M |
| EBITDA | −$28.1M | −$25.4M | −$20.3M | −$20.5M | −$39.2M | −$51.8M | −$68.4M | −$74.4M |
| Net income | −$29.9M | −$30.4M | −$20.3M | −$20.9M | −$41.1M | −$51.8M | −$68.5M | −$74.4M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -26.83 | -17.11 | -3.54 | -2.72 | -2.32 | -1.01 | -1.33 | -0.98 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $385714 | $-0.70 | $-0.73–$-0.68 | 7 |
| 2027 | $3M | $-0.65 | $-0.69–$-0.60 | 6 |
| 2028 | $66M | $-0.33 | $-0.62–$0.34 | 7 |
| 2029 | $192M | $-0.15 | $-0.15–$-0.15 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.15
Price
$5.10
Implied downside
-78%
Peer comparison
Rezolute, Inc. Common Stock (NV)
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
www.rezolutebio.com- Employees
- 71
- IPO / List date
- Dec 23, 2011
- HQ
- REDWOOD CITY, CA
Held by traders on TradeandTell
No one on the platform currently holds RZLT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 157,711 | $481.0K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2020-10-13 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded RZLT yet.
